PARP inhibitors are also effective in Ewing's sarcomas by blocking, on the one hand, PARP1-dependent transcriptional activation effects of ETS gene fusions such as EWS-FLI-1, and by exacerbating DNA damage on the other (Brenner et al. 2012). The gene discussed is PARP1; the disease is Ewing sarcoma.